The global HbA1c testing devices market is growing at a significant rate, expected to grow at a CAGR of 10.1%. Worldwide, the increasing incidences of diabetes and other lifestyle diseases will drive the market growth globally. As per the data by International Diabetes Federation, in 2021, more than 430 Mn people were reported to have diabetes, i.e. 9.3% of the world’s population. The rate is going to increase by 10.3% by 2033 and 10.9% by 2045, i.e. around 700 Mn.
The global electrophysiology devices market accounted for a value of US$ 8,643.1 Mn in 2020 and expected to attain US$ 16,730.2 Mn by 2029. Variables of the market are globally growing older population base coupled with rising prevalence of atrial fibrillation (AF) & cardiovascular diseases (CVDs), technological advancements in electrophysiology devices, and the presence of favorable government initiatives.
Major companies engaged in healthcare market have understood a new paradigm to be in healthcare for women. Healthcare for women in itself presents a separate market with different needs, attitudes and preferences as against healthcare for men. Healthcare marketers understand that women are indispensable customers in the healthcare industry for reasons such as that they account for over 50% of all physician visits, and they are the primary decision makers in healthcare.
The global hemostasis/coagulation market is expected to grow at a CAGR of 8.5% during the forecast period of 2025 to 2033. A coagulation analyzer, also known as a micro-coagulation system, is a piece of equipment that can monitor and assess the rate at which a clot is forming or coagulating. By identifying the presence of blood clots in the blood arteries, this test makes it possible to reduce the risk of having a heart attack, an embolism, or thrombosis. The growth of this market is primarily attributable to an increase in coagulation diagnosis coupled with point-of-care diagnostics as well as an increase in industrial medical device manufacturing capacity.
The global blood typing, grouping and infectious disease screening market will reach US$ 7,078.3 Mn by 2026 from US$ 3,079.8 Mn in 2017, growing at a CAGR of 9.7% during the forecast period from 2018 to 2026. Blood grouping comprises ABO grouping and Rh tests, whereas nucleic acid testing (NAT) and immunoassays are preferred for blood screening to identify the presence of infectious agents.
Oxidative stress is a result of an imbalance between reactive oxygen species and body’s ability to detoxify it. Such discrepancies in the redox state of the cell lead to the generation of peroxides and free radicals that may damage the cell components including lipids, proteins, and DNA. Oxidative stress assay is a method to evaluate the oxidative stress level of cells as sustained oxidative stress can lead to cancer, Parkinson's & Alzheimer’s disease, atherosclerosis and inflammatory diseases among others.
The amniocentesis needles market is set to reach from US$ 166.0 Mn in 2020 to US$ 218.5 Mn by 2029 at a compound annual growth rate (CAGR) of 3.1% during the forecast period from 2021 to 2029. Amniocentesis is frequently performed in prenatal diagnosis to identify any chromosomal abnormalities, neural tube defect and fetal infections during pregnancy. Rising public health awareness and implementation of effective health guidelines pertaining to obstetrics and gynecology drive the amniocentesis needles market growth.
Respiratory Syncytial Virus (RSV) is a single-stranded RNA virus that causes respiratory infections such as pneumonia, bronchiolitis and among others. In tropical climates, RSV infection is more prominent during the rainy season.
The Cystoscope market is expected to grow at a CAGR of 6.1 % during the forecast period of 2021 to 2029. A cystoscope is a thin tube with a camera and light on the end. During a cystoscopy, the tube is inserted through the urethra to be able to image for diagnostic purpose.
The global atrial fibrillation devices market accounted for market value of US$ 4,884.9 Mn in 2017 and expected to attain US$ 17,867.3 Mn by 2026. Worldwide growing geriatric population coupled with rising prevalence of obesity and hypertension are anticipated to nurture the market growth over the forecast period.
The diagnostics market includes instruments, reagents, test kits, software and related services used to detect diseases, assess patient health and support treatment decisions. Major areas include clinical chemistry, molecular diagnostics, immunodiagnostics, hematology, microbiology, genetic testing, companion diagnostics and point-of-care testing. Hospitals, diagnostic laboratories, research institutions, physician offices and home-care users represent the market’s major customers.
The global clinical diagnostics market is projected to increase from USD 87.99 billion in 2025 to USD 150.30 billion by 2035, registering a CAGR of 5.50% from 2026 to 2035. This forecast represents clinical diagnostics; individual segments such as molecular, digital and point-of-care diagnostics may record different growth rates.
The increasing prevalence of cancer, diabetes, cardiovascular disorders and infectious diseases is a major market growth driver. Aging populations and rising awareness of preventive healthcare are increasing the demand for routine testing and early disease detection. Healthcare providers are also using diagnostic tests to monitor treatment response, determine disease risk and select suitable therapies.
Molecular diagnostics is an important growth area because it can identify genetic material, pathogens and disease-related biomarkers with high accuracy. Polymerase chain reaction, next-generation sequencing and other molecular testing technologies are increasingly used in oncology, infectious disease testing and inherited disorder screening. Companion diagnostics are also gaining importance because they help identify patients who are likely to benefit from specific targeted medicines.
Point-of-care and home-based testing represent another major trend. Portable diagnostic systems provide results close to the patient, reducing the time between sample collection and treatment decisions. Demand is growing for rapid tests, connected glucose monitors and other decentralized testing solutions. However, laboratory-based systems remain important for complex tests, high sample volumes and confirmatory analysis.
Artificial intelligence, laboratory automation and digital connectivity are changing diagnostic workflows. Automated sample handling can improve laboratory productivity and reduce manual errors. AI-supported platforms help professionals analyze test results and identify patterns, while connected diagnostic systems enable data transfer between laboratories, hospitals and electronic health records.
Market restraints include high equipment costs, strict approval requirements, reimbursement limitations and shortages of trained laboratory professionals. Differences in test quality and healthcare access may also limit adoption in developing markets. Diagnostic companies must address data security, result accuracy and system compatibility when introducing digital platforms.
North America leads the market due to developed laboratory infrastructure, high testing volumes and early adoption of advanced technologies. Europe maintains strong demand supported by established healthcare systems. Asia-Pacific is expected to offer significant growth opportunities through 2035 due to increasing healthcare expenditure, expanding diagnostic networks and rising disease screening in China, India and Southeast Asia.
Acute Market Reports provides diagnostics market research covering market size, product and technology analysis, disease applications, end users, competitive developments, regional opportunities and forecasts through 2035. These reports support diagnostic companies, laboratories, healthcare providers and investors in making informed business decisions.